Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
出版年份 2023 全文链接
标题
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
作者
关键词
-
出版物
DIABETES & METABOLISM
Volume 49, Issue 5, Pages 101474
出版商
Elsevier BV
发表日期
2023-09-05
DOI
10.1016/j.diabet.2023.101474
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Diabetes and Stroke: What Are the Connections?
- (2023) Ofri Mosenzon et al. Journal of Stroke
- GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Patients With Versus Without Cardiovascular Disease: A Systematic Review, Meta-analysis, and Trial Sequential Analysis
- (2023) Mustafa Kilickap et al. ANGIOLOGY
- Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong
- (2023) David Tak Wai Lui et al. Cardiovascular Diabetology
- Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
- (2023) Jimmy Gonzalez et al. Cardiovascular Diabetology
- Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
- (2023) Pierre Gourdy et al. Cardiovascular Diabetology
- Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
- (2023) Avraham Karasik et al. DIABETES & METABOLISM
- Cardiovascular and Renal Benefits of Novel Diabetes Drugs by Baseline Cardiovascular Risk: A Systematic Review, Meta-analysis, and Meta-regression
- (2023) José M. Rodriguez-Valadez et al. DIABETES CARE
- Comparative efficacy of sodium‐glucose co‐transporter‐2 inhibitors, glucagon‐like peptide‐1 receptor agonists and non‐steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta‐analysis
- (2023) Bao‐Ngoc Nguyen et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: A meta-analysis of randomized controlled trials
- (2023) Guijun He et al. HEART & LUNG
- Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses
- (2023) Shirley V. Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2023) Mainak Banerjee et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes
- (2023) Pradip Mukhopadhyay et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation
- (2023) Sheng‐Nan Chang et al. Journal of the American Heart Association
- Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis
- (2023) Riccardo Proietti et al. Journal of Clinical Medicine
- Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
- (2023) Anjay Rastogi et al. Journal of Clinical Medicine
- Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes
- (2023) Hidekatsu Yanai et al. Cardiology Research
- Differential effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose–response meta-analysis involving 10 randomized clinical trials and 71 553 individuals
- (2023) Donna Shu-Han Lin et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
- (2023) Priyadarshini Balasubramanian et al. STROKE
- Risk of New-onset Stroke in Patients with Type 2 Diabetes with Chronic Kidney Disease on Sodium-glucose Co-transporter-2 Inhibitor Users
- (2023) Gwo-Ping Jong et al. Translational Stroke Research
- Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
- (2023) Yan Xie et al. Lancet Diabetes & Endocrinology
- Effect of SGLT2 Inhibitors on Risk of Stroke in Diabetes: A Meta-Analysis
- (2022) Chunhui Zhang et al. CEREBROVASCULAR DISEASES
- Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
- (2022) Alison K. Wright et al. DIABETES CARE
- Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice
- (2022) Edouard L. Fu et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
- (2022) Irene Caruso et al. Metabolites
- The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
- (2022) Dario Giugliano et al. Cardiovascular Diabetology
- Comparative cardiovascular effectiveness of glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter‐2 inhibitors in patients with type 2 diabetes: A population‐based cohort study
- (2022) Yaa‐Hui Dong et al. DIABETES OBESITY & METABOLISM
- Comparisons of pleiotropic effects of SGLT2 inhibition and GLP-1 agonism on cardiac glucose intolerance in heart dysfunction
- (2022) Belma Turan et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
- (2022) W. David Strain et al. STROKE
- Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists
- (2022) Ronald M. Goldenberg et al. STROKE
- Quality of Care Among Patients with Diabetes and Cerebrovascular Disease. Insights from The Diabetes Collaborative Registry
- (2022) Justin B. Echouffo-Tcheugui et al. AMERICAN JOURNAL OF MEDICINE
- The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis
- (2022) Muhammad Usman Ali et al. CANADIAN JOURNAL OF CARDIOLOGY
- National Trends in the Achievement of Recommended Strategies for Stroke Prevention in U.S. Adults With Type 2 Diabetes, 2001–2018
- (2022) Shihchen Kuo et al. DIABETES CARE
- Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors
- (2022) Donna Shu-Han Lin et al. DIABETOLOGIA
- Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes: an umbrella review of evidence from randomized clinical trials versus real-world observational studies
- (2022) Bojung Seo et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus
- (2022) Seung Eun Lee et al. Diabetes & Metabolism Journal
- Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
- (2022) Lixin Du et al. Frontiers in Cardiovascular Medicine
- Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists
- (2022) Qinchao Wu et al. BIOMEDICINE & PHARMACOTHERAPY
- Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
- (2022) Marta Baviera et al. Cardiovascular Diabetology
- Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
- (2022) André J. Scheen DIABETES & METABOLISM
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2022) Melanie J. Davies et al. DIABETOLOGIA
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
- (2022) Peter Rossing et al. KIDNEY INTERNATIONAL
- Effects of GLP ‐1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and meta‐analysis
- (2022) Michael Kelly et al. PHARMACOTHERAPY
- The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors
- (2022) Meiyuan Dong et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
- (2022) Phyo T. Htoo et al. JAMA Network Open
- Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
- (2022) Lixin Du et al. Frontiers in Cardiovascular Medicine
- Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
- (2022) Bruno Vergès et al. Cardiovascular Diabetology
- GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
- (2022) Nikolaus Marx et al. CIRCULATION
- Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
- (2022) Jedidiah I. Morton et al. DIABETOLOGIA
- From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors
- (2022) Cheng-Yang Hsieh et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis
- (2022) Jiaxi Li et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Caring for Patients With Diabetes in Stroke Neurology
- (2022) Walter N. Kernan et al. STROKE
- The Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Stroke and Atrial Fibrillation: A Systematic Review and Meta-Analysis
- (2022) Kaneez Fatima et al. CURRENT PROBLEMS IN CARDIOLOGY
- Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis
- (2022) Pierre SABOURET et al. Minerva Cardiology and Angiology
- Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
- (2021) Takayuki Yamada et al. Cardiovascular Diabetology
- Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults
- (2021) Elisabetta Patorno et al. DIABETES CARE
- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- (2021) Suetonia C Palmer et al. BMJ-British Medical Journal
- Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?
- (2021) Alice Y.Y. Cheng CIRCULATION
- GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis
- (2021) Thomas Karagiannis et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
- (2021) Moa Lugner et al. Cardiovascular Diabetology
- Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes Mellitus?
- (2021) Bertram Pitt et al. CIRCULATION
- A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists
- (2021) Insiya B. Poonawalla et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
- (2021) Sheyu Li et al. BMJ-British Medical Journal
- The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
- (2021) Donna Shu-Han Lin et al. DIABETOLOGIA
- Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study
- (2021) Christina E. DeRemer et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
- (2021) Emily Brown et al. LANCET
- Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients
- (2021) Xue-Yan Duan et al. MEDICINE
- Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
- (2021) Wen-Hsuan Tsai et al. Scientific Reports
- Cardiovascular Outcomes with GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors in Patients with Type 2 Diabetes
- (2021) Caroline H Nørgaard et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization
- (2021) Beini Lyu et al. AMERICAN JOURNAL OF CARDIOLOGY
- Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
- (2021) Elisabetta Patorno et al. ANNALS OF INTERNAL MEDICINE
- GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
- (2021) Dario Giugliano et al. Cardiovascular Diabetology
- The comparative cardiovascular and renal effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A Scandinavian cohort study
- (2021) Peter Ueda et al. DIABETES OBESITY & METABOLISM
- Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A retrospective multi-institutional study
- (2021) Fu-Chih Hsiao et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis
- (2021) How Ting Ong et al. Journal of Stroke & Cerebrovascular Diseases
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
- (2021) Mei Qiu et al. Frontiers in Cardiovascular Medicine
- Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
- (2020) Fabio Marsico et al. EUROPEAN HEART JOURNAL
- The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
- (2020) Hertzel C Gerstein et al. Lancet Diabetes & Endocrinology
- Invited review. Series: Implications of the recent CVOTs in type 2 diabetes
- (2020) Angela Dardano et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis
- (2020) Konark Malhotra et al. JOURNAL OF NEUROLOGY
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
- (2020) Apostolos Tsapas et al. ANNALS OF INTERNAL MEDICINE
- Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
- (2020) Enrico Longato et al. BMJ Open Diabetes Research & Care
- Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke
- (2020) Fatima Alzahra Al Hamed et al. CLINICAL THERAPEUTICS
- Glucagon like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review
- (2020) Mark P Maskery et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
- (2020) André J. Scheen Nature Reviews Endocrinology
- Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials
- (2020) Xu-Bin Wei et al. Primary Care Diabetes
- GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression
- (2020) Mei Qiu et al. Diabetes Therapy
- Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis
- (2020) Mei Qiu et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?
- (2020) David Thompson VALUE IN HEALTH
- Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis
- (2019) H. Hussein et al. DIABETIC MEDICINE
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
- (2019) Chang Ho Ahn et al. Journal of Stroke
- Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
- (2019) Yue Fei et al. Cardiovascular Diabetology
- Diabetes drugs and stroke risk: Intensive versus conventional glucose‐lowering strategies, and implications of recent cardiovascular outcome trials
- (2019) Soo Lim et al. DIABETES OBESITY & METABOLISM
- Subtype‐Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study
- (2019) Kenichiro Sato et al. JOURNAL OF CLINICAL PHARMACOLOGY
- GLP-1 receptor agonists and cardiovascular protection: A class effect or not?
- (2018) André J. Scheen DIABETES & METABOLISM
- SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis
- (2018) Man Guo et al. DIABETES OBESITY & METABOLISM
- Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
- (2018) André J. Scheen DIABETES RESEARCH AND CLINICAL PRACTICE
- Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation
- (2018) Jeffrey S. Berger et al. JOURNAL OF CARDIAC FAILURE
- Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
- (2018) Elisabetta Patorno et al. BMJ-British Medical Journal
- Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
- (2018) Elisabetta Patorno et al. BMJ-British Medical Journal
- Heart Failure as a Risk Factor for Stroke
- (2018) Woohyeun Kim et al. Journal of Stroke
- Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease
- (2018) Fabrice Bonnet et al. DIABETES & METABOLISM
- The prevalence of Diabetes and its effects on Stroke Outcomes; a meta-analysis and literature review
- (2018) L H Lau et al. Journal of Diabetes Investigation
- Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
- (2017) Bernard Zinman et al. STROKE
- Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
- (2016) Konstantinos P Imprialos et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Conceptual and Technical Challenges in Network Meta-analysis
- (2013) Andrea Cipriani et al. ANNALS OF INTERNAL MEDICINE
- Evaluating the Evidence
- (2008) P. Michael Ho et al. CIRCULATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now